Last edition
News about
Agomab Unveils Plans for Initial Public Offering
Agomab has appointed JP Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen as joint book-running managers for the proposed Initial Public Offering (IPO), marking a key step in its plans to access the public markets.
Lupin Launches Dasatinib Tablets in USA Following FDA Approval
Lupin Limited has announced the launch of dasatinib tablets in multiple strengths in the United States following approval of its Abbreviated New Drug Application from the USA Food and Drug Administration.
FDA Launches PreCheck Pilot to Strengthen Domestic Drug Manufacturing
The USA Food and Drug Administration (FDA) has launched a new pilot initiative aimed at strengthening domestic drug manufacturing and reinforcing the country’s pharmaceutical supply chain.
India's 2026 Budget Sets Stage for Biopharmaceutical Manufacturing Boom: OPPI
The Organisation of Pharmaceutical Producers of India (OPPI) has described the Union Budget 2026 as a pivotal moment in India’s journey to becoming a global biopharmaceutical manufacturing leader.
Piramal Pharma Acquires Global Rights to Kenalog Brand in Up to USD 100 Million Deal
Piramal Pharma has agreed to acquire the global rights to the Kenalog brand and its associated injectable corticosteroid products from Bristol-Myers Squibb in a deal valued at up to USD 100 million. The acquisition will be executed through Piramal’s wholly owned subsidiary, Piramal Critical Care B.V.
Trace Biosciences Secures FDA IND Clearance for First Nerve-Specific Fluorescent Imaging Agent
FDA clears IND application for LGW16-03, enabling Trace Biosciences to begin first-in-human trials of its nerve-targeted imaging agent designed to reduce accidental nerve injuries during surgery.
Illumina has completed its USD 350 million acquisition of SomaLogic, strengthening its multiomics portfolio and expanding large-scale proteomics capabilities to accelerate drug discovery and improve patient outcomes.
Pharming Gets Complete Response Letter from US FDA for Joenja
The US FDA issued a Complete Response Letter to Pharming Group for the supplemental NDA for Joenja, citing the need for additional information to support its use in children aged four to 11 years with activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency.
J&J Wins CHMP Nod for AKEEGA in BRCA-Mutated mHSPC
Backed by positive AMPLITUDE trial results, the CHMP opinion supports AKEEGA in BRCA-mutated mHSPC, showing delayed disease progression and early signs of improved Overall Survival (OS) versus standard of care.
EU recommends Rezurock for CHMP approval to treat chronic GVHD
The CHMP’s positive opinion, backed by clinical trial data and real-world evidence, paves the way for Rezurock’s potential approval in the EU as a new treatment option for adult and paediatric patients aged 12 years and above with late-line chronic graft-vs-host disease.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy